OBJECTIVE: We investigated the efficacy and toxicity of a docetaxel, ifosfamide and nedaplatin regimen as salvage therapy for patients with advanced testicular germ cell tumor.
METHODS: Eleven patients with advanced germ cell tumor refractory or relapsed after cisplatin-based chemotherapy were treated using docetaxel, ifosfamide and nedaplatin. The docetaxel, ifosfamide and nedaplatin regimen comprised docetaxel (75 mg/m2) on Day 1, ifosfamide (2 g/m2) on Days 1-3 and nedaplatin (75 mg/m2) on Day 2 of a 3-week cycle.
RESULTS: Ten (91%) of the 11 patients achieved favorable responses, including complete response in one case and partial response in nine cases. Nine (81%) of the 11 patients have continued to show no evidence of disease after docetaxel, ifosfamide and nedaplatin therapy followed by subsequent surgical resection, with a median follow-up period of 52 months. One patient died of the disease 3 months after completing docetaxel, ifosfamide and nedaplatin chemotherapy. One patient was lost to follow-up with a status of alive with disease. Ten (91%) of the 11 patients developed Grade 4 leukopenia, which was managed using granulocyte colony-stimulating factor. No patients developed sensory neuropathy or renal dysfunction.
CONCLUSIONS: The docetaxel, ifosfamide and nedaplatin regimen was efficacious and well-tolerated as salvage chemotherapy for patients with advanced germ cell tumor.
Written by:
Yamada S, Saito H, Ohara S, Yamashita S, Mitsuzuka K, Namiki S, Miyazato M, Kaiho Y, Ito A, Nakagawa H, Ishidoya S, Arai Y. Are you the author?
Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Reference: Jpn J Clin Oncol. 2013 Apr 25. Epub ahead of print.
doi: 10.1093/jjco/hyt060
PubMed Abstract
PMID: 23619987
UroToday.com Testicular Cancer Section
